低级别蛛网膜下腔出血中的夹层动脉瘤:POGASH注册研究
基于POGASH多中心前瞻性注册数据,回顾分析60例低级别(WFNS IV-V级)蛛网膜下腔出血合并夹层动脉瘤患者,其中54例接受治疗,88.9%为血管内治疗,中位治疗时间6小时。再出血率23.3%,显著高于整体队列,再出血独立预测院内死亡和长期残疾,颈内动脉血泡样动脉瘤与再出血独立相关。
要点
- 低级别SAH合并夹层动脉瘤再出血率高达23.3%,显著高于整体队列。
- 再出血独立预测院内死亡(aOR 7.4)和长期残疾(aOR 0.08)。
- 颈内动脉血泡样动脉瘤与再出血独立相关(aOR 8)。
核心结论
- 低级别SAH合并夹层动脉瘤具有独特的临床影像特征,超早期再出血风险高,强烈影响临床结局。
- 研究提示对该人群超早期或即刻治疗可能获益,尚需进一步验证。
研究设计与样本
- 回顾性分析POGASH多中心前瞻性注册研究数据,纳入2015年1月1日至2024年6月30日连续入组的患者。
- 低级别定义为治疗前WFNS分级IV-V级,共纳入693例低级别SAH患者,其中60例夹层动脉瘤患者进行分析。
- 结局采用改良Rankin量表评估,夹层动脉瘤按Mizutani分类。
主要发现
- 54例接受治疗的患者中,88.9%接受血管内治疗(血管闭塞48%、血流导向26%、弹簧圈栓塞26%),11.1%接受手术治疗。
- 从症状出现到治疗的中位时间(IQR)为6(4-9)小时。
- 再出血发生于23.3%的患者,显著高于整体队列(p < 0.048)。
- 再出血独立预测院内死亡(校正OR 7.4;95% CI 1.5-35.1;p = 0.011)和长期残疾(校正OR 0.08;95% CI 0.007-0.98;p = 0.04)。
- 颈内动脉血泡样动脉瘤与再出血独立相关(校正OR 8;95% CI 1.2-50;p = 0.027)。
临床怎么用
- 对低级别SAH合并夹层动脉瘤患者,应警惕超早期再出血风险,考虑超早期或即刻治疗。
- 血管内治疗是主要治疗方式,但需根据动脉瘤类型个体化选择。
- 颈内动脉血泡样动脉瘤患者再出血风险更高,需密切监测并积极干预。
局限性
- 回顾性分析前瞻性注册数据,可能存在选择偏倚。
- 夹层动脉瘤亚组样本量较小(60例),结论需进一步验证。
- 超早期治疗获益为提示性,尚需前瞻性研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Intracranial dissecting aneurysms (DAs) are rare and challenging lesions, often associated with high rates of rebleeding and poor clinical outcomes. There is limited evidence regarding optimal treatment strategies, timing, and outcomes, especially in the context of poor-grade subarachnoid hemorrhage (pSAH). The authors aimed to describe the clinical features and treatment outcomes of patients with DAs included in a national multicentric registry of pSAH and to identify independent outcome predictors within this subpopulation. METHODS: The authors conducted a retrospective analysis of prospectively collected data from the multicenter Poor-Grade Aneurysmal Subarachnoid Hemorrhage (POGASH) registry, including consecutive patients admitted between January 1, 2015, and June 30, 2024. Poor grade was defined as a pretreatment World Federation of Neurosurgical Societies grade IV-V. Outcomes were assessed using the modified Rankin Scale. DAs were classified according to the Mizutani classification. RESULTS: Of the 693 consecutive pSAH patients included in the registry, data from 60 patients with DA were analyzed. Among the 54 treated patients, 88.9% underwent endovascular treatment (vessel occlusion [48%], flow diversion [26%], and coiling [26%]), while 11.1% were treated surgically. The median (IQR) time to treatment was 6 (4-9) hours from symptom onset. Rebleeding occurred in 23.3% of patients, significantly more frequently than in the overall cohort (p < 0.048). Rebleeding independently predicted in-hospital mortality (adjusted OR 7.4; 95% CI 1.5-35.1; p = 0.011) and long-term disability (adjusted OR 0.08; 95% CI 0.007-0.98; p = 0.04). Internal carotid artery blister aneurysms were independently associated with rebleeding (adjusted OR 8; 95% CI 1.2-50; p = 0.027). CONCLUSIONS: In the context of pSAH, DAs are characterized by distinct clinicoradiological features and carry a significant risk of ultra-early rebleeding, which strongly influences clinical outcome. These findings suggest a potential benefit of ultra-early or immediate treatment in this patient population, pending further validation.
引用
- Lozupone E, Signorelli F, Barchetti G, et al. Dissecting aneurysm in poor-grade subarachnoid hemorrhage. J Neurosurg. 2025. PMID: 41202279. doi:10.3171/2025.6.JNS25834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。